Literature DB >> 27001422

Cardiac salvage by tweaking with beta-3-adrenergic receptors.

Jean-Luc Balligand1.   

Abstract

Overstimulation of the orthosympathetic system leads to cardiovascular cell and tissue damage through prolonged activation of β-1-2 adrenergic receptors (BARs). The more recent identification of the third isotype of BAR (B3AR) in cardiac myocytes and endothelial cells with a distinctive coupling and effect on cardiac function and remodelling introduced a new facet to this paradigm. In particular, B3AR is up-regulated in cardiac disease and less prone to homologous desensitization, which may reinforce its influence on the diseased myocardium. Mice with transgenic cardiac-specific expression of the human B3AR are protected from cardiac hypertrophy and fibrosis in response to neurohormonal stimulation. B3AR has also been implicated in cardiac protection after ischaemia-reperfusion and the benefits of exercise on the heart. Many of these salvage mechanisms are mediated by B3AR coupling to nitric oxide synthase (eNOS and nNOS) and downstream cGMP/protein kinase G signalling. Notably, B3AR exerts antioxidant protective effects on these and other signalling elements, which may subserve its protective properties in the setting of chronic heart failure. Additional vasorelaxing properties and paracrine NO-mediated signalling by B3AR in endothelium, together with systemic metabolic effects on beige/brown fat complete the pleiotropic protective properties of this new therapeutic target. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  adrenergic receptor; catecholamines; heart failure; hypertrophy; nitric oxide; remodelling

Mesh:

Substances:

Year:  2016        PMID: 27001422     DOI: 10.1093/cvr/cvw056

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  19 in total

Review 1.  GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.

Authors:  Alessandro Cannavo; Walter J Koch
Journal:  Cell Signal       Date:  2017-01-07       Impact factor: 4.315

2.  Adrenergic Receptors in Individual Ventricular Myocytes: The Beta-1 and Alpha-1B Are in All Cells, the Alpha-1A Is in a Subpopulation, and the Beta-2 and Beta-3 Are Mostly Absent.

Authors:  Bat-Erdene Myagmar; James M Flynn; Patrick M Cowley; Philip M Swigart; Megan D Montgomery; Kevin Thai; Divya Nair; Rumita Gupta; David X Deng; Chihiro Hosoda; Simon Melov; Anthony J Baker; Paul C Simpson
Journal:  Circ Res       Date:  2017-02-20       Impact factor: 17.367

Review 3.  Healthful aging mediated by inhibition of oxidative stress.

Authors:  Stephen F Vatner; Jie Zhang; Marko Oydanich; Tolga Berkman; Rotem Naftalovich; Dorothy E Vatner
Journal:  Ageing Res Rev       Date:  2020-10-19       Impact factor: 10.895

4.  Mirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarction.

Authors:  Xavier Rossello; Antonio Piñero; Rodrigo Fernández-Jiménez; Javier Sánchez-González; Gonzalo Pizarro; Carlos Galán-Arriola; Manuel Lobo-Gonzalez; Jean Paul Vilchez; Jaime García-Prieto; Jose Manuel García-Ruiz; Ana García-Álvarez; David Sanz-Rosa; Borja Ibanez
Journal:  J Cardiovasc Transl Res       Date:  2018-08-02       Impact factor: 4.132

5.  Myofibroblast β2 adrenergic signaling amplifies cardiac hypertrophy in mice.

Authors:  Atsuki Imaeda; Shota Tanaka; Kota Tonegawa; Shota Fuchigami; Masanori Obana; Makiko Maeda; Miho Kihara; Hiroshi Kiyonari; Simon J Conway; Yasushi Fujio; Hiroyuki Nakayama
Journal:  Biochem Biophys Res Commun       Date:  2019-01-23       Impact factor: 3.575

6.  β 3 Adrenergic Receptor Stimulation Promotes Reperfusion in Ischemic Limbs in a Murine Diabetic Model.

Authors:  Kristen J Bubb; Dhanya Ravindran; Siân P Cartland; Meghan Finemore; Zoe E Clayton; Michael Tsang; Owen Tang; Mary M Kavurma; Sanjay Patel; Gemma A Figtree
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 7.  Targeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade.

Authors:  Alessandro Cannavo; Walter J Koch
Journal:  J Cardiovasc Pharmacol       Date:  2017-02       Impact factor: 3.105

Review 8.  New Treatment Strategies for Alcohol-Induced Heart Damage.

Authors:  Joaquim Fernández-Solà; Ana Planavila Porta
Journal:  Int J Mol Sci       Date:  2016-09-29       Impact factor: 5.923

Review 9.  Molecular pathways of oestrogen receptors and β-adrenergic receptors in cardiac cells: Recognition of their similarities, interactions and therapeutic value.

Authors:  J O Machuki; H Y Zhang; S E Harding; H Sun
Journal:  Acta Physiol (Oxf)       Date:  2017-10-30       Impact factor: 6.311

Review 10.  New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging.

Authors:  Claudio de Lucia; Akito Eguchi; Walter J Koch
Journal:  Front Pharmacol       Date:  2018-08-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.